In ongoing clinical trials, the CD16 UCAR-T cell therapy has been investigated in HER2-positive cancer, in multiple myeloma (MM), and in non-Hodgkin’s lymphoma [65,89]. The gene discussed is FCGR3A; the disease is cancer.